98%
921
2 minutes
20
Background And Purpose: A commercial 2.5 MV beam has been clinically available for beam's-eye-view imaging in radiotherapy, offering improved contrast-to-noise ratio (CNR) compared to therapeutic beams, due to the softer spectrum. Previous research suggested that imaging performance could be improved using a low-Z diamond target to reduce the self-absorption of diagnostic energy photons. The aim of this study was to 1) investigate the feasibility of two 2.5 MV diamond target beamline configurations and 2) characterize the dosimetry and planar image quality of these novel low-Z beams.
Materials And Methods: The commercial 2.5 MV beam was modified by replacing the copper target with sintered diamond. Two beamlines were investigated: a carousel-mounted diamond target beamline and a 'conventional' beamline, with the diamond target in the target arm. Planar image quality was assessed in terms of spatial resolution and CNR.
Results: Due to image artifacts, image quality could not be assessed for the carousel-mounted low-Z target beam. The 'conventional' 2.5 MV low-Z beam quality was softer by 2.7% compared to the commercial imaging beam, resulting in improved CNR by factors of up to 1.3 and 1.7 in thin and thick phantoms, respectively. In regard to spatial resolution, the 'conventional' 2.5 MV low-Z beam slightly outperformed the commercial imaging beam.
Conclusion: With a simple modification to the 2.5 MV commercial beamline, we produced an improved energy spectrum for imaging. This 2.5 MV diamond target beam proved to be an advantageous alternative to the commercial target configuration, offering both superior resolution and CNR.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807593 | PMC |
http://dx.doi.org/10.1016/j.phro.2020.10.007 | DOI Listing |
J Thorac Oncol
September 2025
Institut du Thorax Curie-Montsouris, Paris, France; Paris-Saclay University, UVSQ-Versailles, France.
Introduction: Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies are associated with dermatologic adverse events (AEs), which can affect quality of life (QoL). COCOON was conducted to assess prophylactic management and improve treatment experience.
View Article and Find Full Text PDFJAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
Cell
September 2025
Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic address:
Adaptation of intestinal helminths to vertebrates involved the evolution of strategies to attenuate host tissue damage to support parasite reproduction and dissemination of offspring to the environment. Helminths initiate the IL-25-mediated tuft cell-type 2 innate lymphoid cell (ILC2) circuit that enhances barrier protection of the host, although viable parasites can target and limit this pathway. We used IL-25 alone to create small intestinal adaptation, marked by anatomic and immunologic changes that persisted months after induction.
View Article and Find Full Text PDFJ Am Chem Soc
September 2025
State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, P. R. China.
Emerging evidence underscores the regulatory roles of nonamyloidogenic regions in controlling the aggregation dynamics and cytotoxicity of amyloidal proteins, but the mechanism remains unclear. Herein we investigated how flanking sequences modulate the conformational heterogeneity in the p53 238-262 amyloid segment using scanning tunneling microscopy (STM). By comparing the wild-type (wt) and three pathogenic mutations (R248W, R248Q, R249S) in the noncore regions, we reveal that flanking alterations remodel β-sheet aggregates and induce conformational plasticity in β-strand ensembles through the generation of novel conformational substates and selective elimination of existing conformational substates.
View Article and Find Full Text PDFBlood Cancer Discov
September 2025
Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from pre-existing, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole genome sequencing data, we could time genomic antigen escape in 4 out of 11 RRMM patients.
View Article and Find Full Text PDF